# MaxCyte (MXCT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MXCT
## Company Profile
- Ticker: MXCT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom and listed in the U
- Tags: Gene Therapy
## Stock Data
- Close: 1.27 USD
- Market cap: 131759656.56 USD
- Last updated: 2026-08-12
## Business Overview
### Cell Engineering Platform
MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies.
### ExPERT Platform
The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale while preserving cell viability and function.
### Strategic Platform Licenses
Cell-therapy developers use MaxCyte technology under Strategic Platform License agreements that can generate instrument, consumable, milestone, and commercial revenue as partnered programs advance.
### SeQure Services
SeQure expands the offering into gene-editing risk assessment and analytical services, helping developers evaluate editing outcomes and potential off-target effects.
### Enterprise Partnerships
MaxCyte also licenses multiple platform technologies at the enterprise level. Its Genentech agreement extends this model across research, clinical development, and potential commercial manufacturing workflows.
## Why The Stock Is Moving

The latest monitored company update is “MaxCyte Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Recent News
- 2026-08-12 20:05 EST — [MaxCyte Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MXCT/maxcyte-reports-second-quarter-2026-financial-results-f3d7fe63) — Source: MaxCyte
- 2026-07-21 12:05 EST — [MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development](https://biopharmsignal.com/news/MXCT/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-t-3ff788d8) — Source: MaxCyte
- 2026-07-15 20:05 EST — [MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026](https://biopharmsignal.com/news/MXCT/maxcyte-to-report-second-quarter-2026-financial-results-on-august-12-2026-1e03d6dc) — Source: MaxCyte
- 2026-06-23 13:00 EST — [VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering](https://biopharmsignal.com/news/MXCT/vectorbuilder-partners-with-maxcyte-to-advance-clinical-grade-cell-engineering-00dc0502) — Source: MaxCyte
- 2026-05-12 20:06 EST — [MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-first-quarter-2026-financial-results-and-reiterates-full-year-2026-guidance) — Source: MaxCyte